Rare Disease: A year in review
As more investments have been made in developing and commercializing treatments for rare diseases, the experience and expertise of our CRA teams have grown....
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
For 25 years, our global team of senior experts has helped Life Science firms anticipate trends and break through strategic barriers. CRA’s fit-for-purpose designs go beyond a single project, to build a true strategic partnership, providing cross-functional support across industry stakeholders and geographies. Clients rely on CRA’s institutional knowledge and subject matter expertise to provide an independent perspective to address core business issues, drive change, and align internal stakeholders.
As more investments have been made in developing and commercializing treatments for rare diseases, the experience and expertise of our CRA teams have grown....
With changes to the pricing and access processes such as the new Accord Cadre and the soon-to-be implemented ATU reform likely to impact pricing and access of...
CRA is a proud sponsor of the congress. Cecile Matthews and Bhavesh Patel present their session titled “Project LEOPARD (Long-term Evolution & Outlook for...
CRA is a proud sponsor of the congress. Lev Gerlovin and Bhavesh Patel present the Pricing & Reimbursement track session titled “Project LEOPARD: future...